StreetInsider.com News Articles

Form 4 Amylyx Pharmaceuticals, For: Jul 09 Filed by: Mazzariello Gina

Mon, 13 Jul 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260713/26762381.html

Form 4 Amylyx Pharmaceuticals, For: Jul 09 Filed by: Mazzariello Gina

Mon, 13 Jul 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260713/26762381.html

Form 144 Amylyx Pharmaceuticals, Filed by: Mazzariello Gina

Thu, 09 Jul 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260709/26753516.html

Form 144 Amylyx Pharmaceuticals, Filed by: Mazzariello Gina

Thu, 09 Jul 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260709/26753516.html

Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $40 at Guggenheim

Thu, 25 Jun 2026 07:40:19 -0400

(Updated - June 25, 2026 7:40 AM EDT)

Guggenheim analyst Seamus Fernandez raised the price target on Amylyx Pharmaceuticals inc. (NASDAQ: AMLX) to $40.00 (from $30.00) while maintaining a Buy rating.

The analyst commented: "We are elevating AMLX to our BEST IDEA (from Top Pick) and raising our PT to $40 (from $30) ahead of the pivotal Phase 3 LUCIDITY readout in 3Q26 for avexitide in PBH. We strongly believe LUCIDITY will be positive and pave the way for AMLX to dominate the $6B+ US PBH market for years to come. Our model updates reflect: (1) Increased GLP-1R antagonism penetration in severe

Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $40 at Guggenheim

Thu, 25 Jun 2026 07:40:19 -0400

(Updated - June 25, 2026 7:40 AM EDT)

Guggenheim analyst Seamus Fernandez raised the price target on Amylyx Pharmaceuticals inc. (NASDAQ: AMLX) to $40.00 (from $30.00) while maintaining a Buy rating.

Amylyx ALS drug shows no serious adverse events in Phase 1 trial

Tue, 23 Jun 2026 07:00:26 -0400

Amylyx Pharmaceuticals (NASDAQ: AMLX) presented early data from the Phase 1 LUMINA trial of its investigational drug AMX0114 for amyotrophic lateral sclerosis (ALS) at the European Network to Cure ALS (ENCALS) Meeting 2026 in Madrid, Spain.

In Cohort 1, which evaluated the lowest dose level of 12.5 mg in 12 participants, AMX0114 showed no drug-related serious adverse events and no serious neurological adverse events. Biomarker levels, including spectrin breakdown product 145, neurofilament light, and phosphorylated neurofilament heavy, remained near baseline.

LUMINA (NCT06665165) is a multinational, randomized, double-blind, placebo-controlled, multiple ascending dose trial evaluating AMX0114 across four dose levels. The trial is expected

Amylyx ALS drug shows no serious adverse events in Phase 1 trial

Tue, 23 Jun 2026 07:00:26 -0400

LUMINA (NCT06665165) is a multinational, randomized, double-blind, placebo-controlled, multiple ascending dose trial evaluating AMX0114 across four dose levels. The trial is expected

Amylyx ALS drug shows no serious adverse events in Phase 1 trial

Tue, 23 Jun 2026 07:00:26 -0400

LUMINA (NCT06665165) is a multinational, randomized, double-blind, placebo-controlled, multiple ascending dose trial evaluating AMX0114 across four dose levels. The trial is expected

Amylyx ALS drug shows no serious adverse events in Phase 1 trial

Tue, 23 Jun 2026 07:00:26 -0400

LUMINA (NCT06665165) is a multinational, randomized, double-blind, placebo-controlled, multiple ascending dose trial evaluating AMX0114 across four dose levels. The trial is expected

Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026